Virios therapeutics announces fourth quarter and full year 2022 financial results

Atlanta, march 14, 2023 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”), today announced financial results for the fourth quarter and full year ended december 31, 2022.
VIRI Ratings Summary
VIRI Quant Ranking